Assessment and Development of the Antifungal Agent Caspofungin for Aerosolized Pulmonary Delivery

Invasive Pulmonary Aspergillosis (IPA) and Pneumocystis jiroveci Pneumonia (PCP) are serious fungal pulmonary diseases for immunocompromised patients. The brand name drug CANCIDAS(®) (Caspofungin acetate for injection) is FDA approved to treat IPA, but is only 40% effective. Efficacious drug levels...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Iching G., Ryckman, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067632/
https://www.ncbi.nlm.nih.gov/pubmed/33916988
http://dx.doi.org/10.3390/pharmaceutics13040504

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067632/
https://www.ncbi.nlm.nih.gov/pubmed/33916988
http://dx.doi.org/10.3390/pharmaceutics13040504

Ejemplares similares